Announcements Trials
Browse Landscape

Phase

Phase 2 13Phase 3 3Phase 1/2 2Phase EARLY_PHASE1 1

Status

Withdrawn 3Completed 3Terminated 2Active not recruiting 2Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Adenocarcinoma Of Esophagus 1

Interventions

fludarabine 5Cyclophosphamide 5Surgical Procedures, Operative 2Standard of Care 2Immune Checkpoint Inhibitors 2Bevacizumab 2venetoclax 1tucatinib 1trifluridine tipiracil drug combination 1tremelimumab 1trastuzumab deruxtecan 1tislelizumab 1tipiracil 1spartalizumab 1sotorasib 1selpercatinib 1posaconazole 1pembrolizumab 1peginterferon alfa-2b 1osimertinib 1montelukast 1malic acid 1icotinib 1gallium maltolate 1encorafenib 1eliglustat 1durvalumab 1daratumumab 1cannabigerol 1asciminib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Not yet recruiting × durvalumab × Clear all
NCT06824363 2026-01-30

ProofPrincip IntraTu TCells SinglDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu

University of California, Irvine

Phase EARLY_PHASE1 Not yet recruiting
34 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus

Data powered by HemOnc (CC BY 4.0) Colophon âš¡